---
document_datetime: 2025-12-29 07:03:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-teva-pharma.html
document_name: pioglitazone-teva-pharma.html
version: success
processing_time: 0.125416
conversion_datetime: 2025-12-30 02:58:11.648378
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pioglitazone Teva Pharma

[RSS](/en/individual-human-medicine.xml/67033)

##### Withdrawn

This medicine's authorisation has been withdrawn

pioglitazone Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 June 2021, the European Commission withdrew the marketing authorisation for Pioglitazone Teva Pharma (pioglitazone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pioglitazone Teva Pharma was granted marketing authorisation in the EU on 26 March 2012 for treatment of type 2 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2017. The product had not been marketed in the EU since 2021.

Pioglitazone Teva Pharma is a generic medicine of Actos. There are other generic medicinal products of Actos authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Pioglitazone Teva Pharma is updated to indicate that the marketing authorisation is no longer valid.

Pioglitazone Teva Pharma : EPAR - Summary for the public

Reference Number: EMA/239161/2012

English (EN) (632.55 KB - PDF)

**First published:** 11/04/2012

**Last updated:** 30/08/2022

[View](/en/documents/overview/pioglitazone-teva-pharma-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-727)

български (BG) (807 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/bg/documents/overview/pioglitazone-teva-pharma-epar-summary-public_bg.pdf)

español (ES) (697.43 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/es/documents/overview/pioglitazone-teva-pharma-epar-summary-public_es.pdf)

čeština (CS) (774.16 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/cs/documents/overview/pioglitazone-teva-pharma-epar-summary-public_cs.pdf)

dansk (DA) (694.42 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/da/documents/overview/pioglitazone-teva-pharma-epar-summary-public_da.pdf)

Deutsch (DE) (697.91 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/de/documents/overview/pioglitazone-teva-pharma-epar-summary-public_de.pdf)

eesti keel (ET) (692.86 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/et/documents/overview/pioglitazone-teva-pharma-epar-summary-public_et.pdf)

ελληνικά (EL) (811.42 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/el/documents/overview/pioglitazone-teva-pharma-epar-summary-public_el.pdf)

français (FR) (700.23 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fr/documents/overview/pioglitazone-teva-pharma-epar-summary-public_fr.pdf)

italiano (IT) (696.38 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/it/documents/overview/pioglitazone-teva-pharma-epar-summary-public_it.pdf)

latviešu valoda (LV) (769.32 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lv/documents/overview/pioglitazone-teva-pharma-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (720.16 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lt/documents/overview/pioglitazone-teva-pharma-epar-summary-public_lt.pdf)

magyar (HU) (766.16 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/hu/documents/overview/pioglitazone-teva-pharma-epar-summary-public_hu.pdf)

Malti (MT) (753.84 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/mt/documents/overview/pioglitazone-teva-pharma-epar-summary-public_mt.pdf)

Nederlands (NL) (697.58 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/nl/documents/overview/pioglitazone-teva-pharma-epar-summary-public_nl.pdf)

polski (PL) (773.68 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pl/documents/overview/pioglitazone-teva-pharma-epar-summary-public_pl.pdf)

português (PT) (636.93 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pt/documents/overview/pioglitazone-teva-pharma-epar-summary-public_pt.pdf)

română (RO) (723.28 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/ro/documents/overview/pioglitazone-teva-pharma-epar-summary-public_ro.pdf)

slovenčina (SK) (751.19 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sk/documents/overview/pioglitazone-teva-pharma-epar-summary-public_sk.pdf)

slovenščina (SL) (747.81 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sl/documents/overview/pioglitazone-teva-pharma-epar-summary-public_sl.pdf)

Suomi (FI) (692.9 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fi/documents/overview/pioglitazone-teva-pharma-epar-summary-public_fi.pdf)

svenska (SV) (693.61 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sv/documents/overview/pioglitazone-teva-pharma-epar-summary-public_sv.pdf)

Pioglitazone Teva Pharma : EPAR - Risk-management-plan summary

English (EN) (624.74 KB - PDF)

**First published:** 21/07/2020

**Last updated:** 30/08/2022

[View](/en/documents/rmp-summary/pioglitazone-teva-pharma-epar-risk-management-plan-summary_en.pdf)

## Product information

Pioglitazone Teva Pharma : EPAR - Product Information

English (EN) (959.18 KB - PDF)

**First published:** 11/04/2012

**Last updated:** 30/08/2022

[View](/en/documents/product-information/pioglitazone-teva-pharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-582)

български (BG) (1.94 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/bg/documents/product-information/pioglitazone-teva-pharma-epar-product-information_bg.pdf)

español (ES) (978.96 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/es/documents/product-information/pioglitazone-teva-pharma-epar-product-information_es.pdf)

čeština (CS) (1.65 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/cs/documents/product-information/pioglitazone-teva-pharma-epar-product-information_cs.pdf)

dansk (DA) (984.64 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/da/documents/product-information/pioglitazone-teva-pharma-epar-product-information_da.pdf)

Deutsch (DE) (1007.88 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/de/documents/product-information/pioglitazone-teva-pharma-epar-product-information_de.pdf)

eesti keel (ET) (973.89 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/et/documents/product-information/pioglitazone-teva-pharma-epar-product-information_et.pdf)

ελληνικά (EL) (1.95 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/el/documents/product-information/pioglitazone-teva-pharma-epar-product-information_el.pdf)

français (FR) (1.03 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fr/documents/product-information/pioglitazone-teva-pharma-epar-product-information_fr.pdf)

hrvatski (HR) (277.57 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/hr/documents/product-information/pioglitazone-teva-pharma-epar-product-information_hr.pdf)

íslenska (IS) (968.23 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/is/documents/product-information/pioglitazone-teva-pharma-epar-product-information_is.pdf)

italiano (IT) (989.29 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/it/documents/product-information/pioglitazone-teva-pharma-epar-product-information_it.pdf)

latviešu valoda (LV) (1.7 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lv/documents/product-information/pioglitazone-teva-pharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lt/documents/product-information/pioglitazone-teva-pharma-epar-product-information_lt.pdf)

magyar (HU) (292.54 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/hu/documents/product-information/pioglitazone-teva-pharma-epar-product-information_hu.pdf)

Malti (MT) (1.68 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/mt/documents/product-information/pioglitazone-teva-pharma-epar-product-information_mt.pdf)

Nederlands (NL) (977.21 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/nl/documents/product-information/pioglitazone-teva-pharma-epar-product-information_nl.pdf)

norsk (NO) (966.02 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/no/documents/product-information/pioglitazone-teva-pharma-epar-product-information_no.pdf)

polski (PL) (1.67 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pl/documents/product-information/pioglitazone-teva-pharma-epar-product-information_pl.pdf)

português (PT) (969.93 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pt/documents/product-information/pioglitazone-teva-pharma-epar-product-information_pt.pdf)

română (RO) (1.07 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/ro/documents/product-information/pioglitazone-teva-pharma-epar-product-information_ro.pdf)

slovenčina (SK) (1.65 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sk/documents/product-information/pioglitazone-teva-pharma-epar-product-information_sk.pdf)

slovenščina (SL) (1.64 MB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sl/documents/product-information/pioglitazone-teva-pharma-epar-product-information_sl.pdf)

Suomi (FI) (963.66 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fi/documents/product-information/pioglitazone-teva-pharma-epar-product-information_fi.pdf)

svenska (SV) (968.59 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sv/documents/product-information/pioglitazone-teva-pharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0024 21/06/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pioglitazone Teva Pharma : EPAR - All Authorised presentations

English (EN) (714.39 KB - PDF)

**First published:** 11/04/2012

**Last updated:** 30/08/2022

[View](/en/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-24)

български (BG) (727 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/bg/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (633.78 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/es/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (629.36 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/cs/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (592.3 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/da/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (598.53 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/de/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (639.72 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/et/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (665.26 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/el/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_el.pdf)

français (FR) (601.37 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fr/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (595.29 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/is/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (640.92 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/it/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (681.76 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lv/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (688.14 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lt/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (739.48 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/hu/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (771.16 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/mt/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (592.12 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/nl/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (593.17 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/no/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (633.13 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pl/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (642.82 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pt/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (614.64 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/ro/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (660.65 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sk/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (673.08 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sl/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (633.68 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fi/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (668.41 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sv/documents/all-authorised-presentations/pioglitazone-teva-pharma-epar-all-authorised-presentations_sv.pdf)

Pioglitazone Teva Pharma : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (603.04 KB - PDF)

**First published:** 11/04/2012

**Last updated:** 30/08/2022

[View](/en/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-184)

български (BG) (702.48 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/bg/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (603.28 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/es/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (701.41 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/cs/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (597.49 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/da/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (604.29 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/de/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (602.76 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/et/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (700.43 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/el/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (603.65 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fr/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (603.74 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/is/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (602.93 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/it/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (704.87 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lv/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (670.64 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/lt/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (667.86 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/hu/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (702.97 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/mt/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (603.51 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/nl/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (603.34 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/no/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (702.57 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pl/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (598.19 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/pt/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (667.91 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/ro/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (694 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sk/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (693.11 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sl/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (597.99 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/fi/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (603.65 KB - PDF)

**First published:**

11/04/2012

**Last updated:**

30/08/2022

[View](/sv/documents/conditions-member-states/pioglitazone-teva-pharma-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Pioglitazone Teva Pharma Active substance pioglitazone hydrochloride International non-proprietary name (INN) or common name pioglitazone Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BG03

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Pioglitazone is indicated in the treatment of type-2 diabetes mellitus as **monotherapy:**

- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.

Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

## Authorisation details

EMA product number EMEA/H/C/002410

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10

Opinion adopted 19/01/2012 Marketing authorisation issued 26/03/2012 Withdrawal of marketing authorisation 22/06/2021 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pioglitazone Teva Pharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (738.01 KB - PDF)

**First published:** 14/07/2014

**Last updated:** 30/08/2022

[View](/en/documents/procedural-steps-after/pioglitazone-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pioglitazone Teva Pharma : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/844210/2011

English (EN) (950 KB - PDF)

**First published:** 11/04/2012

**Last updated:** 30/08/2022

[View](/en/documents/assessment-report/pioglitazone-teva-pharma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pioglitazone Teva Pharma

Adopted

Reference Number: EMA/CHMP/756105/2011

English (EN) (645.26 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 30/08/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pioglitazone-teva-pharma_en.pdf)

**This page was last updated on** 30/08/2022

## Share this page

[Back to top](#main-content)